JPMorgan starts coverage of Arcus Biosciences stock at Overweight

Published on 10/16/2026 at 02:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The USD 41.00 target for Arcus Biosciences stock came on October 14, 2026. ARC-20 data cover 121 patients on October 20.

Arcus advances its pipeline

JPMorgan began coverage with a USD 41.00 target on October 14, 2026.
Second-quarter revenue reached USD 41.0 million against USD 21.98 million expected.
Arcus will present ARC-20 data for 121 patients on October 20, 2026.

RCUS, US03969F1093, Illustration mit AI erstellt.

Arcus Biosciences (ISIN US03969F1093) received a USD 41.00 price target when Markets Insider reported JPMorgan's Overweight initiation on October 14, 2026. The call puts casdatifan at the center of the investment case before Arcus presents new ARC-20 data on October 20, 2026.

JPMorgan backs casdatifan

JPMorgan's target rests on casdatifan, an investigational HIF-2a inhibitor being studied in clear cell renal cell carcinoma. The drug is being developed as a potential treatment backbone across several lines of therapy, while regulatory approval has not yet been granted.

The analyst case includes worldwide unadjusted peak sales of USD 4.0 billion by 2035, including USD 3.6 billion in the United States, according to Markets Insider. Those figures are a model assumption, not reported revenue.

Three milestones shaped the case

On August 5, 2026, Arcus reported second-quarter revenue of USD 41.00 million, down 74.4 percent from the prior-year quarter, while revenue exceeded the USD 21.98 million consensus estimate, according to MarketBeat. On September 22, 2026, Arcus announced an investor event covering casdatifan combinations and monotherapy data.

On October 14, 2026, JPMorgan initiated coverage with an Overweight rating and a USD 41.00 target. The sequence shows why clinical data, rather than current revenue growth, is the central valuation variable for this clinical-stage biotechnology company.

What comes next for the pipeline?

Business Wire said the October 20, 2026 event will cover first-line combinations in 30 patients, a second-line casdatifan and cabozantinib cohort of 43 patients, and late-line monotherapy data from 121 patients. Arcus expects to complete enrollment in PEAK-1 and start the Phase 3 PEAK-20 study by year-end 2026.

Reporting dates are approaching

The next scheduled catalyst is the ARC-20 investor event on October 20, 2026. Nasdaq-listed calendar information also identifies November 10, 2026 as the next earnings date, according to Nasdaq.

Pipeline data set the near-term test

Arcus is a clinical-stage biopharmaceutical company listed on the NYSE under ticker RCUS. The October data event offers a concrete test of whether casdatifan can support a broader development strategy across treatment settings.